ZURICH, Switzerland, Dec. 20 /PRNewswire/ -- In a press release published this evening, Sulzer AG announced legal steps to be taken against one-time subsidiary Sulzer Medica. This action represents no new development. Dr. Stephan Rietiker, CEO of Sulzer Medica, commented on the action of Sulzer AG by saying: "It is our clear intent to quickly and fairly compensate any affected patients in the USA. We will not be deterred from this path by third parties. Sulzer AG remains welcome to participate in the settlement." Sulzer Medica's subsidiary companies develop, produce, and distribute medical implants and biological materials for cardiovascular and orthopedic markets worldwide. The product array includes artificial joint, vertebral, and dental implants, trauma products, heart valves, synthetic blood vessels and stents for vascular and non-vascular obstructions. (Swiss Stock Market symbol: SMEN, New York Stock Exchange symbol: SM). THE SAFE HARBOR STATEMENTS UNDER THE U.S. PRIVATE SECURITIES LITIGATION REFORM ACT 1995 This report contains forward-looking statements including, but not limited to, projections of future performance of materials and products, financial conditions, results of operations and cash flows, containing risks and uncertainties. These statements are subject to change based on known risks detailed from time to time in the Company's Securities and Exchange Commission filings and other known and unknown risks and various other factors which could cause the actual results or performance to differ materially from the statements made herein. This news release is available on the Internet at: http://www.sulzermedica.com. The company's quarterly report is available on the Sulzer Medica corporate web site at http://www.sulzermedica.com "Investors" / "Financial reports". SOURCE Sulzer Medica -0- 12/20/2001 /CONTACT: Beatrice Tschanz, +41-1-308-38-66, or fax, +41-1-308-35-06, or Andy Bantel, +41-1-308-37-69, or mobile, +41-79-231-56-62, or fax, +41-1-308-35-06, or email@example.com, both of Sulzer Medica Corp. Communications; or Investors, Michael Staheli, +41-1-308-38-64, or fax, +41-1-308-35-08, or firstname.lastname@example.org, or U.S., Jim Johnson, +1-713-561-6376, or fax, +1-713-561-6380, or email@example.com, both of Sulzer Medica/ /Web site: http://www.sulzermedica.com / (SM) CO: Sulzer Medica; Sulzer AG ST: Switzerland IN: HEA MTC SU: LAW -0- Dec/20/2001 19:52 GMT
Sulzer Medica: Nothing New from Sulzer AG
Press spacebar to pause and continue. Press esc to stop.